{"id":"NCT03924427","sponsor":"Bristol-Myers Squibb","briefTitle":"An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis","officialTitle":"An Open-Label, Single-arm, Multi-Center, Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Japanese Subjects With Moderate-to-Severe Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-10","primaryCompletion":"2021-03-24","completion":"2021-03-24","firstPosted":"2019-04-23","resultsPosted":"2022-11-02","lastUpdate":"2022-11-02"},"enrollment":74,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"BMS-986165","otherNames":[]}],"arms":[{"label":"BMS-986165","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate BMS-986165 given to Japanese participants with moderate-to-severe psoriasis.","primaryOutcome":{"measure":"Static Physician's Global Assessment (sPGA) 0/1 Response as a Number of Participants With a sPGA Score of 0 or 1 at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Plaque Psoriasis 6 mg QD","deltaMin":52,"sd":null},{"arm":"Generalized Pustular Psoriasis 6 mg QD","deltaMin":0,"sd":null},{"arm":"Erythrodemic Psoriasis 6 mg QD","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":27,"countries":["Japan"]},"refs":{"pmids":["40304108","40066907"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":74},"commonTop":["Nasopharyngitis","Acne","Constipation","Stomatitis","Periodontitis"]}}